You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 四环医药(0460.HK)涨3.49% 独家代理的韩国肉毒毒素产品“乐提葆Letybo 50U”获批于中国市场推出
格隆汇 02-10 14:45
格隆汇2月10日丨四环医药(0460.HK)午后异动,由跌2.64%拉升至涨3.49%,报2.37港元,成交近3亿港元,总市值224亿港元。四环医药今日午间宣布,由公司独家代理并由韩国生物制药公司Hugel, Inc.生产的注射用A型肉毒毒素Letybo® 50U(商品名:乐提葆®)于2021年2月10日正式获中国国家药品监督管理局批准于市场推出,将与2020年10月21日率先获批上市的乐提葆®Letybo® 100U联袂为中国用户提供塑美选择。乐提葆®Letybo®作为第四个获准在中国市场推出的A型肉毒毒素,也是韩国同类产品中的首个。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account